Panacea Biotec Reminds Physical Shareholders to Submit PAN & KYC Details
Panacea Biotec Limited is reminding physical shareholders to submit mandatory PAN and KYC details as per SEBI directives. This is crucial for updating records, receiving future payments electronically, and facilitating share dematerialization. Shareholders are urged to comply promptly to avoid service disruptions and ensure smooth transactions.
This is a standard regulatory compliance communication and does not indicate any significant new business, financial changes, or strategic shifts for the company.
The announcement is a routine regulatory compliance communication reminding shareholders to update their details. It does not contain any positive or negative financial or business developments.
Panacea Biotec Limited has issued a reminder letter dated September 15, 2026, to shareholders holding shares in physical mode. This communication is in compliance with SEBI Circulars (SEBI/HO/38/13/(4)2026 -MIRSD -POD/I/4298/2026 dated February 06, 2026, and SEBI/HO/MIRSD/MIRSD -POD -1/P/CIR/2024/81 dated June 10, 2024) mandating the submission of PAN, KYC details, and bank account information.
The company, along with its Registrar and Transfer Agent, Skyline Financial Services Private Limited, is requesting shareholders to furnish these details to update their records and to facilitate the dematerialization of their shares. Failure to update PAN and contact details by April 1, 2024, means dividends or interest will be paid only through electronic mode after compliance. Furthermore, physical shareholders will not be able to lodge grievances or avail services from the RTA until these details are updated.
Shareholders are also encouraged to provide nomination details for smoother transmission of securities. The necessary forms (ISR-1, ISR-2, SH-13, ISR-3, SH-14) and required supporting documents can be downloaded from the company's website or the RTA's website. The company emphasizes that its securities are traded only in dematerialized form and urges physical shareholders to convert their holdings to demat form for ease of transaction.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.